J&J Unit To Pay $5.9M To End Mont. Risperdal Row
A Johnson & Johnson unit on Thursday agreed to pay $5.9 million to resolve a suit brought by Montana's attorney general claiming the company promoted its antipsychotic drug Risperdal as safe...To view the full article, register now.
Already a subscriber? Click here to view full article